高剂量率后装治疗子宫颈癌

High dose-rate afterloading in the treatment of cervical cancer of the uterus.

作者信息

Cai S M, Wang X E, Wang Q

机构信息

Dept. of Gynecologic Oncology, Cancer Hospital, Shanghai Medical University, China.

出版信息

Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):335-8.

PMID:2921134

Abstract

From January 1981 to December 1983, 380 patients with cervical carcinoma of uterus were treated with high dose-rate intracavitary afterloading therapy (Ralstron-20B) and 60Co external irradiation. All of these cases have been followed over 3-5 years. The 5-year survival rates for Stages I, II, III, and IV were 100%, 81.5%, 73.9%, and 0% respectively. The over all 5-year survival rate was 79.1%. The results were comparable to that of conventional radium therapy in 1980 (5-year survival rate for radium group: Stage I 50%, Stage II 72.2%, Stage III 52.2%, Stage IV 0%). The moderate and severe rectal reactions in this series were 11.8% and 1.6% (radium group moderate 6.0%, severe 2.2%), which were higher than that of radium group. The incidence of bladder reaction was 7.1%. The problems of high dose-rate intracavitary therapy and the combination therapy with intracavitary and external irradiation are discussed in this paper.

摘要

1981年1月至1983年12月，380例子宫颈癌患者接受了高剂量率腔内后装治疗（Ralstron - 20B）及钴 - 60体外照射。所有这些病例均随访了3至5年。Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期的5年生存率分别为100%、81.5%、73.9%和0%。总体5年生存率为79.1%。这些结果与1980年传统镭疗的结果相当（镭疗组5年生存率：Ⅰ期50%，Ⅱ期72.2%，Ⅲ期52.2%，Ⅳ期0%）。本系列中中度和重度直肠反应分别为11.8%和1.6%（镭疗组中度6.0%，重度2.2%），高于镭疗组。膀胱反应发生率为7.1%。本文讨论了高剂量率腔内治疗以及腔内与体外照射联合治疗的问题。